Medicare GLP-1 Bridge: Affordable Access to Weight Loss Medications
The federal government has launched an initiative, Medicare GLP-1 Bridge, to offer Medicare and Medicare Advantage beneficiaries affordable access to GLP-1 weight loss medications. Effective immediately, eligible participants can obtain select brand-name GLP-1 drugs for $50 a month under this program, which will continue until the end of 2027. These medications, including products from Eli Lilly and Novo Nordisk, have gained FDA approval for weight management.
This trial program marks the first effort to cover glucagon-like peptide-1 receptor agonists (GLP-1s) for weight loss for older adults through insurance. However, individuals already receiving insurance coverage for GLP-1s for conditions like diabetes or sleep apnea are ineligible. The Medicare initiative aims to reduce financial burdens, as Dr. Mehmet Oz, administrator of the Centers for Medicare & Medicaid Services (CMS), emphasized, noting the high costs as a significant barrier.
Juliette Cubanski from the research nonprofit KFF highlighted that, although many Medicare enrollees qualify as overweight or obese, only some will access the program. Eligibility requires a body mass index (BMI) of 35 or above, or a BMI of 27 coupled with another health condition such as heart attack, stroke, or prediabetes. Beneficiaries with conditions like sleep apnea, diabetes, or fatty liver disease may seek coverage through Medicare Part D plans related to their specific conditions.
To pursue eligibility, Medicare recipients should contact their healthcare provider to facilitate the prescription and authorization process. Participants will incur a $50 monthly fee, which does not impact their insurance deductibles or out-of-pocket limits, as Medicare subsidizes these costs rather than Part D insurers.
Without permanent congressional authorization, the program is set to conclude by December 31, 2027, leaving long-term coverage for weight loss drugs limited. CMS is monitoring outcomes and considering alternative pilot programs such as BALANCE. Ongoing negotiations with pharmaceutical companies aim to lower drug costs further. Dr. Oz stressed the importance of data collection to evaluate the program's future and encouraged legislative discussions on the matter.
The popularity and effectiveness of GLP-1 medications are rising, but high costs remain a barrier. For individuals like Gloria Dralla, the new Medicare program has enabled continued access to beneficial medications for her weight management. However, others like Katie Smith, who do not meet eligibility or face high costs, remain frustrated by the program's limitations.